Search clinical trials for: LM001

Total 23 results

AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis (CAMEO)

Primary Sclerosing Cholangitis (PSC)

United States, United Kingdom, Canada
Karolinska Institutet
deFair Medical AB

Active, not recruiting

Probiotics for Weight Loss

Overweight

Sweden
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, United Kingdom, Poland, France
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
Mirum Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network

Completed

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (ITCH)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) (IMAGINE)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.; Childhood Liver Disease Research and Education...

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
AmDerma
International Dermatology Research, Inc.

Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Dominican Republic
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Shanghai Jiao Tong University School of Medicine

Recruiting

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Medullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine Carcinoma

China
Mirum Pharmaceuticals, Inc.

Completed

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK)

Biliary Atresia

United States, United Kingdom, China, Taiwan, Germany, Poland, Singapore, Vietnam
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Alphamab Jilin Co., Ltd.

Unknown

Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women

Infertility, Female
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Completed

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Healthy Volunteers

United States
He Huang
Lingyi Biotech Co., Ltd.

Recruiting

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I (LY-M001)

Gaucher Disease Type I

China
NovaBiotics Ltd.
Agility Clinical, Inc.; PSR Group B.V.

Completed

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations (CARE-CF1)

Cystic Fibrosis

United States, United Kingdom, Italy
LaNova Medicines Limited

Suspended

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Malignant Tumors

China

3

Subscribe